Articles · Symptoms
Urinary Incontinence After Menopause
Why type matters: the same hormone that drives symptoms can worsen them, depending on how it is delivered.
Sourced from peer-reviewed research and clinical guidelines, cited at the end of this article. How we write about your body.
Urinary incontinence is one of the most common and least discussed consequences of the menopausal transition. Studies put the rate in postmenopausal women between 45% and 63%, which makes it more common than hot flashes in this group.[1] Many women do not raise it with clinicians, either from embarrassment or an assumption that nothing can be done.
Understanding the two main types of incontinence is the first step to understanding why treatments differ, and why well-meant approaches sometimes make things worse.
Two Types, Two Mechanisms
Stress urinary incontinence (SUI) is leaking triggered by a rise in pressure inside the abdomen: coughing, sneezing, laughing, lifting, or exercise. It happens when the urethral sphincter cannot resist the pressure spike. SUI is more common in younger women and is often linked to pelvic floor weakness after childbirth.
Urge urinary incontinence (UUI) is leaking that comes with a sudden, intense urge that cannot be put off. It may happen with little physical trigger: the sound of running water, putting a key in the door, or simply walking toward a bathroom. UUI reflects overactivity of the detrusor muscle (the bladder wall), which contracts before the bladder is full.
Before menopause, SUI is the dominant type. After menopause, UUI and mixed incontinence become the dominant pattern.[1] This shift has a hormonal explanation.
How Losing Estrogen Drives Urge Incontinence
Estrogen receptors are spread throughout the lower urinary tract: in the urethra, the base of the bladder, and the pelvic floor muscles.[2] Estrogen supports the stretch and blood supply of urethral tissue, sphincter function, and the sensitivity threshold of the detrusor muscle.
When estrogen falls, the urethral lining thins, sphincter function weakens, and the detrusor becomes more sensitive and prone to involuntary contractions.[2] The result is a bladder that signals fullness early and reacts strongly to minor stimuli, driving urgency and frequency.
The same tissue thinning that causes vaginal dryness (genitourinary syndrome of menopause, GSM) extends to the urethra and the base of the bladder. These structures are connected anatomically and hormonally, which is why treating GSM often helps urinary symptoms too.
The Systemic HRT Paradox
A counterintuitive finding from the Women’s Health Initiative trial: systemic (oral) HRT was linked to a statistically significant worsening of urinary incontinence and more new incontinence (both stress and urge types) compared with placebo.[3]
This seems to contradict the estrogen mechanism described above. The proposed explanation is that oral estrogen, through its first pass through the liver, may affect collagen production differently from local tissue effects. Whatever the mechanism, the clinical takeaway is clear: systemic HRT should not be used to treat urinary incontinence, and women with existing incontinence who start systemic HRT should know their symptoms may worsen.
The picture with local (vaginal) estrogen is different. Vaginal estrogen acts directly on the urethral and bladder tissue with very little reaching the rest of the body, and evidence shows benefit for urgency and frequency specifically.[4] Randomised trials have found improvements in urge incontinence symptoms and fewer trips to the bathroom at night.
What Works for Stress Incontinence
Pelvic floor muscle training (PFMT) has the strongest evidence for SUI. Meta-analyses consistently show that supervised PFMT reduces how often, how much, and how badly you leak, more than no treatment.[5] The training involves repeatedly contracting and relaxing the pelvic floor muscles in progressively harder programmes.
Three things determine how well it works:
- Supervised training with a pelvic health physiotherapist produces better results than unsupervised exercises
- Results need consistency over at least 3 months
- Many women contract abdominal or buttock muscles by mistake; targeting the right muscles matters
For SUI that does not respond to conservative management, surgical options (mid-urethral sling procedures) have strong evidence for effectiveness.
What Works for Urge Incontinence
For UUI, treatment targets the overactive detrusor. The first-line approaches are behavioural.
Bladder training means gradually extending the time between bathroom visits and using suppression techniques (pelvic floor contractions, distraction) when urgency comes. The goal is retraining bladder capacity and reducing the urgency response. Studies show fewer urgency episodes with consistent bladder training.
Local vaginal estrogen reduces urgency and frequency in women with postmenopausal UUI, with effects usually appearing within 6 to 12 weeks of regular use.[4]
Anticholinergic and beta-3 agonist medications (oxybutynin, solifenacin, mirabegron) reduce detrusor overactivity with drugs. They work but carry side effects (dry mouth, constipation, and cognitive effects in older women, especially with anticholinergics) that affect tolerability.
Starting the Clinical Conversation
Given how common it is and the range of effective treatments, urinary incontinence in menopause is worth a clinical conversation. Whether leaking happens with activity, with urgency, or both determines which treatment path fits.
Questions worth raising with a GP or continence specialist:
- Which type of incontinence is dominant?
- Is a referral to a pelvic health physiotherapist appropriate?
- Would local vaginal estrogen fit alongside or instead of other treatment?
References
[1] Li, Y., et al. (2024). The link between menopause and urinary incontinence: a systematic review. Frontiers in Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC11550778/
[2] Robinson, D., Cardozo, L. (2003). The role of estrogens in female lower urinary tract dysfunction. Urology, 62(4 Suppl 1), 45-51. See also: Local oestrogen for pelvic floor disorders: a systematic review. https://pmc.ncbi.nlm.nih.gov/articles/PMC4575150/
[3] Hendrix, S. L., Cochrane, B. B., Nygaard, I. E., et al. (2005). Effects of estrogen with and without progestin on urinary incontinence. JAMA, 293(8), 935-948. https://doi.org/10.1001/jama.293.8.935
[4] Rahn, D. D., Ward, R. M., Sanses, T. V., et al. (2015). Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. International Urogynecology Journal, 26(1). See also: Local oestrogen for pelvic floor disorders. https://pmc.ncbi.nlm.nih.gov/articles/PMC4575150/
[5] Dumoulin, C., Cacciari, L. P., Hay-Smith, E. J. C. (2018). Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database of Systematic Reviews, 10, CD005654. https://doi.org/10.1002/14651858.CD005654.pub4
Teala surfaces health patterns to help you and your doctor make informed decisions. It does not diagnose conditions or replace medical advice. Always consult a qualified healthcare professional about your symptoms and treatment.